Sticker Tumor

A Sticker Tumor, formally known as Canine Transmissible Venereal Tumor (CTVT), is a unique form of cancer that is transmitted between dogs through direct physical contact, most commonly during mating. Unlike virtually all other cancers, which arise from the affected individual's own mutated cells, CTVT is caused by the transfer of living tumor cells from one dog to another. The transplanted cells engraft in the new host and proliferate to form tumors, making this one of only a handful of naturally occurring clonally transmissible cancers known to science.

The condition was first described by the Russian veterinarian Mstislav Novinsky in 1876 and later characterized extensively by the American pathologist Gruby Sticker, from whom the common name derives. Remarkably, every CTVT cell in existence today traces its lineage back to a single ancestral dog that lived an estimated 6,000 to 11,000 years ago. The tumor cells have persisted as an independent cellular lineage, passed from dog to dog across millennia and continents, accumulating genetic changes along the way while retaining the core capacity for transmission and growth.

CTVT is found worldwide but is most prevalent in tropical and subtropical regions where large populations of free-roaming, sexually intact dogs facilitate transmission. The disease occurs in both male and female dogs, though the anatomical distribution of tumors may differ. In regions with effective spay and neuter programs and controlled dog populations, the incidence of CTVT is substantially lower.

Despite its alarming mode of transmission, CTVT is one of the most treatable cancers in veterinary oncology. The tumor responds exceptionally well to chemotherapy, and cure rates with standard protocols exceed 90 percent. Understanding the biology, transmission, and treatment of this unusual neoplasm is important for dog owners, particularly those in endemic regions or those who adopt dogs from areas where the disease is common.

The primary mode of CTVT transmission is the physical transfer of viable tumor cells from an affected dog to a susceptible host during activities that involve direct mucosal or skin-to-skin contact. Mating is the most common route of transmission, as the friction and microtrauma that occur during copulation create ideal conditions for tumor cells to detach from existing lesions and implant in the genital mucosa of the partner. Both male and female dogs can transmit and acquire the disease during sexual contact.

Transmission is not limited to mating. CTVT cells can be transferred through licking, sniffing, or biting behaviors that bring intact mucosa or abraded skin into contact with tumor tissue. This explains the occurrence of tumors in extragenital locations, including the nasal cavity, oral mucosa, and skin of the face and perineal region. Dogs that engage in social grooming or investigative sniffing of infected individuals are at risk, even in the absence of sexual contact.

The tumor cells themselves are the infectious agent, which makes CTVT fundamentally different from virally induced cancers. No virus or other pathogen mediates the transmission. The transferred cells are allogeneic, meaning they are genetically distinct from the host. The tumor evades the host's immune system through several mechanisms, including downregulation of major histocompatibility complex (MHC) class I molecules on the cell surface, which allows the foreign cells to escape immune recognition during the initial growth phase.

Young, sexually intact dogs in free-roaming populations are at the highest risk of infection due to increased sexual activity and social contact. Immunocompromised dogs, including those with concurrent infections or poor nutritional status, may also be more susceptible to tumor engraftment. Neutering significantly reduces the risk of transmission by decreasing roaming behavior and eliminating mating as a route of exposure.

The clinical presentation of CTVT depends on the anatomical location of the tumor, with genital tumors being the most commonly observed. In male dogs, tumors typically arise on the penile mucosa or the bulbus glandis and present as single or multiple nodular, friable, cauliflower-like masses that bleed easily on contact. Owners may first notice bloody or serosanguinous discharge from the prepuce, which is often the presenting complaint. The affected penis may be difficult to retract, and the dog may lick the area excessively.

In female dogs, CTVT most commonly affects the vaginal and vestibular mucosa. Tumors appear as protruding, reddish, irregularly shaped masses that may cause a persistent bloody vaginal discharge. In some cases, the tumors grow large enough to protrude from the vulva. Owners may observe the dog straining during urination or defecation if the mass creates mechanical obstruction, and affected females may show increased frequency of urination.

Extragenital CTVT occurs in a significant minority of cases and can involve the nasal passages, oral cavity, conjunctiva, or skin. Nasal tumors may cause unilateral nasal discharge, sneezing, epistaxis, and facial deformity. Oral tumors can present as masses on the gums, lips, or tongue, leading to difficulty eating, drooling, and oral bleeding. Cutaneous tumors appear as firm, raised nodules on the skin, often in areas that were in direct contact with an infected animal.

While CTVT is primarily a localized disease, metastasis can occur in a small percentage of cases, particularly in immunosuppressed dogs or in cases that have been present for extended periods without treatment. Metastatic sites include regional lymph nodes, skin distant from the primary site, liver, spleen, kidneys, lungs, and the central nervous system. Metastatic disease is associated with systemic signs including weight loss, lethargy, and organ-specific symptoms depending on the sites involved.

Diagnosis of CTVT is generally straightforward in endemic areas when a sexually intact dog presents with a characteristic friable, hemorrhagic genital mass. However, laboratory confirmation is always recommended to distinguish CTVT from other tumors that can occur in the same anatomical locations, including squamous cell carcinoma, mast cell tumor, lymphoma, and fibrosarcoma.

Cytological examination of a fine-needle aspirate or impression smear from the tumor surface is the most practical and widely used diagnostic method. CTVT cells have a distinctive cytological appearance: they are round to oval with a large, centrally placed nucleus, prominent nucleoli, and a moderate amount of pale blue cytoplasm containing characteristic clear cytoplasmic vacuoles. These vacuoles, which appear as discrete round clear spaces, are a hallmark feature that experienced cytologists can identify rapidly. The cells are relatively uniform in appearance, and mitotic figures are frequently observed.

Histopathological examination of a tissue biopsy provides definitive confirmation and allows assessment of tumor architecture, depth of invasion, and mitotic index. The tumor is composed of sheets of round cells with minimal supporting stroma, and the histological pattern is consistent across cases worldwide, reflecting the clonal origin of the disease. Immunohistochemistry can aid in diagnosis, as CTVT cells characteristically express vimentin and are variably positive for lysozyme, while being negative for cytokeratin, CD3, and CD79a markers.

Additional diagnostic tests may be warranted in certain cases. Regional lymph node aspiration should be performed if nodes are enlarged, to screen for metastatic spread. Thoracic radiographs and abdominal ultrasonography are recommended in advanced or longstanding cases to evaluate for distant metastasis. Complete blood count and serum chemistry should be obtained before initiating chemotherapy to establish baseline organ function and identify any concurrent conditions that could affect treatment.

Chemotherapy with vincristine sulfate is the standard of care for CTVT and is remarkably effective. Vincristine is a vinca alkaloid that inhibits cell division by disrupting microtubule formation during mitosis, and CTVT cells are exquisitely sensitive to its effects. The typical protocol involves intravenous administration of vincristine at a dose of 0.5 to 0.7 milligrams per square meter of body surface area, given once weekly until the tumor has completely resolved, which usually requires four to eight treatments.

Response to vincristine therapy is typically rapid and dramatic. Visible tumor regression often begins within one to two weeks of the first treatment, and most dogs achieve complete remission within four to six weeks. Treatment should be continued for at least one to two doses beyond clinical resolution of the tumor to minimize the risk of recurrence. The complete response rate to vincristine monotherapy exceeds 90 percent in most published studies, making CTVT one of the most chemotherapy-responsive tumors in veterinary oncology.

Side effects of vincristine are generally mild at standard doses. The most common adverse effect is gastrointestinal upset, including reduced appetite, mild nausea, and occasional vomiting or diarrhea. Myelosuppression, particularly neutropenia, can occur and is monitored with periodic complete blood counts during treatment. Peripheral neuropathy, manifested as mild weakness or changes in gait, is a recognized but uncommon side effect. Extravasation of vincristine during injection must be avoided, as the drug is a severe vesicant that can cause significant tissue necrosis if it leaks outside the vein.

In cases that do not respond to vincristine alone, combination chemotherapy protocols may be employed. Doxorubicin has shown efficacy as a second-line agent, either alone or in combination with vincristine. Cyclophosphamide and other alkylating agents have also been used successfully in vincristine-resistant cases. Radiation therapy can be considered for localized tumors that are refractory to chemotherapy, though this is rarely necessary.

While chemotherapy is the preferred treatment for CTVT, surgical excision may be considered in certain clinical situations. Small, well-circumscribed, easily accessible tumors can sometimes be removed surgically with adequate margins. However, surgery alone carries a higher recurrence rate compared to chemotherapy because CTVT frequently infiltrates surrounding tissues in ways that are not grossly visible, making complete excision difficult. For this reason, surgery is typically recommended as an adjunctive rather than primary treatment modality.

Surgical debulking may be beneficial in cases with very large tumors that are causing significant mechanical obstruction or hemorrhage. Removing the bulk of the tumor mass can alleviate clinical signs and may improve the response to subsequent chemotherapy by reducing the overall tumor burden. In rare cases where tumors are causing urethral obstruction or severe dysphagia, surgical intervention may be necessary as an emergency measure before definitive chemotherapy can be initiated.

Radiation therapy is an effective alternative for CTVT, with complete response rates comparable to those achieved with vincristine chemotherapy. A typical radiation protocol involves delivery of 15 to 25 gray in fractions over several treatment sessions. Radiation is particularly useful for tumors in anatomical locations that are difficult to access surgically and for cases that have not responded to chemotherapy. The principal limitations of radiation therapy are the need for general anesthesia at each session, the specialized equipment required, and the limited availability of radiation facilities in veterinary practice.

Immunotherapy and immunomodulatory approaches have been investigated in research settings. The observation that CTVT spontaneously regresses in some immunocompetent dogs has stimulated interest in harnessing the immune system therapeutically. Autologous and allogeneic tumor cell vaccines, cytokine therapy, and immune checkpoint modulation have all shown varying degrees of promise in experimental models, though none has yet replaced vincristine as the standard of care in clinical practice.

One of the most fascinating aspects of CTVT biology is the tumor's complex interaction with the host immune system, which determines whether the tumor progresses, stabilizes, or spontaneously regresses. The natural history of CTVT in immunocompetent dogs typically follows a predictable pattern: an initial progressive growth phase lasting several months, followed by a stable phase, and then in many cases a regression phase in which the immune system mounts an effective antitumor response that eliminates the tumor.

During the progressive phase, the tumor actively suppresses the host immune response through multiple mechanisms. CTVT cells downregulate expression of MHC class I and class II molecules, making them less visible to cytotoxic T lymphocytes and natural killer cells. The tumor also secretes immunosuppressive cytokines, including transforming growth factor beta (TGF-beta) and interleukin-6, which create a local immunosuppressive microenvironment that inhibits the function of infiltrating immune cells.

The transition from progression to regression is associated with a shift in the immune landscape within and around the tumor. Infiltration of the tumor by CD4-positive and CD8-positive T lymphocytes increases markedly, and the expression of MHC molecules on tumor cells is restored, presumably driven by interferon-gamma secreted by the infiltrating lymphocytes. This immune recognition triggers a robust antitumor response that leads to tumor destruction over a period of weeks to months.

Spontaneous regression is most likely in young, immunocompetent dogs with good nutritional status and no concurrent immunosuppressive conditions. In immunocompromised dogs, including those with severe parasitic burdens, malnutrition, concurrent infections, or very young puppies with immature immune systems, the progressive phase may persist indefinitely, and metastasis is more likely to occur. Understanding this immune dynamic has practical implications, as it supports the use of immunostimulatory strategies alongside conventional chemotherapy and underscores the importance of addressing concurrent health problems that may impair immune function.

Prevention of CTVT centers on reducing the opportunities for transmission between dogs. The most effective preventive measure is surgical sterilization through spaying and neutering. Neutered dogs are significantly less likely to roam, engage in mating behavior, or have direct mucosal contact with infected animals. In endemic regions, community-wide spay and neuter programs have been shown to reduce the prevalence of CTVT substantially over time by simultaneously decreasing the reservoir of infection and the population at risk.

Responsible pet ownership practices play a critical role in prevention. Dogs should be supervised during outdoor activities, and contact with stray or free-roaming dogs of unknown health status should be minimized. In areas where CTVT is endemic, owners should be particularly vigilant about preventing their dogs from interacting with unfamiliar animals. Breeding dogs should be examined by a veterinarian before mating to ensure that neither partner harbors genital tumors.

For dogs being imported or adopted from regions where CTVT is prevalent, a thorough veterinary examination including inspection of the genital mucosa is essential before the dog is introduced into a new community. Dogs rescued from stray populations in tropical and subtropical countries should be considered at elevated risk, and any suspicious lesions should be sampled for cytological evaluation. Early detection and treatment prevent transmission to other dogs and improve individual outcomes.

Public health education in endemic communities is an important component of CTVT control. Dog owners should be informed about the existence and transmission of the disease, the importance of neutering, and the availability of effective treatment. In many parts of the world, stigma or lack of awareness about CTVT leads to delayed treatment, during which affected dogs continue to serve as sources of transmission. Veterinary outreach programs that provide affordable diagnostics and treatment in underserved communities can make a significant impact on disease prevalence.

The prognosis for dogs with localized CTVT treated with vincristine chemotherapy is excellent. Complete remission rates consistently exceed 90 percent across studies conducted in diverse geographic and clinical settings, and recurrence following complete remission is uncommon. Most dogs treated appropriately are considered cured, and long-term follow-up studies show that the vast majority of dogs remain tumor-free after completing therapy.

Recurrence, when it does occur, is most often seen in dogs that were treated with an insufficient number of vincristine doses or in which treatment was discontinued before complete tumor resolution. For this reason, adherence to the full treatment protocol, including continuation of chemotherapy for one to two doses beyond gross tumor disappearance, is critically important. Dogs that experience recurrence after an adequate initial course of vincristine usually respond well to retreatment with the same agent.

The prognosis for dogs with metastatic CTVT is more guarded but is still far better than for most metastatic cancers. Vincristine chemotherapy can achieve responses even in cases with regional lymph node involvement, and some dogs with distant metastases have been successfully treated with combination chemotherapy protocols. However, metastatic disease requires more prolonged and aggressive treatment, and the complete response rate is lower than for localized tumors.

Factors associated with a less favorable prognosis include severe immunosuppression, very large tumor burden at the time of diagnosis, metastatic spread to multiple organ systems, and concurrent debilitating diseases that limit the dog's ability to tolerate chemotherapy. Puppies and dogs with severe malnutrition or heavy parasitic infections may require stabilization and supportive care before chemotherapy can be safely initiated. With appropriate comprehensive management, even many of these challenging cases can achieve durable remissions.

CTVT holds a unique position in biology as one of only a few known naturally occurring clonally transmissible cancers, the others being Devil Facial Tumor Disease in Tasmanian devils and a recently identified transmissible leukemia in bivalve mollusks. The extraordinary longevity of the CTVT cell lineage, which has persisted for thousands of years as a parasitic cellular organism passed between host dogs, makes it one of the oldest known continuously surviving mammalian cell lines and a subject of intense scientific interest.

Genomic analyses of CTVT cells collected from dogs on every inhabited continent have revealed that the tumor originated from a single founder animal, likely an ancient dog or wolf-like canid. The original tumor genome has accumulated tens of thousands of somatic mutations over its long evolutionary history, providing a remarkable record of mutational processes acting over millennia. Studies of these mutation patterns have yielded insights into the rates and signatures of somatic mutation in mammalian cells that would be impossible to obtain through any other means.

The ability of CTVT to evade immune destruction across genetically diverse hosts has made it a valuable model for studying tumor immunology and immune evasion mechanisms. The tumor's strategy of downregulating MHC expression during the progressive phase and the host's eventual ability to overcome this evasion in the regression phase mirror dynamics seen in many human cancers. Research on CTVT immune interactions has contributed to broader understanding of how tumors manipulate the immune system and how immunotherapy might overcome these defenses.

From an evolutionary perspective, CTVT represents a fascinating example of a selfish genetic element that has escaped the constraints of its original organism and become an independent parasitic entity. The tumor cells no longer serve the interests of any individual dog but instead perpetuate themselves by exploiting the social and reproductive behaviors of their hosts. This concept has profound implications for our understanding of the boundaries between organisms and the potential for cancer cells to evolve into transmissible parasites under the right ecological conditions.